Department of Neurosurgery, Cedars Sinai Medical Center, 127 S San Vicente Blvd., Suite A6600, Los Angeles, CA, 90048, USA.
School of Medicine, Stanford University, Stanford, CA, USA.
Angiogenesis. 2018 Feb;21(1):23-35. doi: 10.1007/s10456-017-9578-1. Epub 2017 Oct 9.
Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide and the one with the worst prognosis. In this study, we assessed the hypothesis that the balance of circulating pro- and antiangiogenic factors plays a role in the evolution of the disease and can be used as a potential marker for the disease course and a target for treatment. Seventy-four patients with severe ICAD were enrolled in this prospective observational study, medically optimized, and followed for 6 months. Thirteen pro- and eight antiangiogenic factors were measured in the participants' serum using a sandwich multiplex ELISA. Angiogenic profiles were calculated using principal component analysis. We tested the association between angiogenic profiles and recurring cerebrovascular events despite intensive medical therapy, disability at 6 months after enrollment, and angiographic neovascularization in patients who failed medical treatment and underwent indirect revascularization surgery. There is a strong association between a functionally antiangiogenic profile and recurrent stroke or TIA in patients with ICAD (OR = 7.2, CI 2.4-34.4). Multivariable regression analysis showed that this antiangiogenic profile was also associated with poor functional status after 6 months (p = 0.002), independent from other clinical features such as history of previous stroke, diabetes, and age. In patients who failed medical management and underwent indirect revascularization surgery, high endostatin and angiostatin levels were also associated with low angiographic neovascularization (p = 0.02). The results of this study point to the striking importance of antiangiogenesis as a determinant of ICAD patient prognosis and suggest a possible new target for therapy.
颅内动脉粥样硬化性疾病(ICAD)是全球范围内最常见的中风原因之一,也是预后最差的原因之一。在这项研究中,我们假设循环中促血管生成和抗血管生成因子的平衡在疾病的进展中发挥作用,并可以作为疾病过程的潜在标志物和治疗靶点。本前瞻性观察研究纳入了 74 例严重的 ICAD 患者,对其进行了医学优化,并随访了 6 个月。使用夹心多重 ELISA 法测量了参与者血清中的 13 种促血管生成因子和 8 种抗血管生成因子。使用主成分分析计算了血管生成谱。我们测试了血管生成谱与尽管进行了强化药物治疗但仍发生复发性脑血管事件、入组后 6 个月时残疾以及药物治疗失败并接受间接血运重建手术的患者的血管新生之间的关联。在 ICAD 患者中,功能性抗血管生成谱与复发性中风或 TIA 之间存在很强的关联(OR=7.2,CI 2.4-34.4)。多变量回归分析表明,这种抗血管生成谱也与 6 个月后功能状态不良相关(p=0.002),独立于其他临床特征,如既往中风史、糖尿病和年龄。在药物治疗失败并接受间接血运重建手术的患者中,高内皮抑素和血管抑素水平也与低血管新生相关(p=0.02)。这项研究的结果表明,抗血管生成作为 ICAD 患者预后的决定因素具有重要意义,并提示了一种可能的新治疗靶点。